Johnson & Johnson announces approval of OPSYNVI for pulmonary arterial hypertension patients 25-Mar-2024 By Liza Laws In a significant milestone for pulmonary arterial hypertension (PAH) patients, Johnson & Johnson has announced the approval of OPSYNVI.
Soft mist inhaler for PAH result of joint venture between Thaerapy and Resyca 19-Jun-2023 By Liza Laws A soft mist inhaler made by Resyca BV, a joint venture of Medspray Pharma BV and Recipharm AB, is being brought to patients with pulmonary arterial hypertension (PAH).
Single tablet treatment on the horizon for pulmonary arterial hypertension 31-May-2023 By Liza Laws Patients with pulmonary arterial hypertension (PAH) may be able to take a single tablet instead of multiple types if a new drug is approved.